Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients

Case Reports in Immunology
Enrico BrunettaGiorgio W Canonica

Abstract

Presently, there is inconclusive evidence regarding the most effective treatment for idiopathic nonhistaminergic acquired angioedema (InH-AAE). Omalizumab may, however, prove to be a promising option. This case report describes two patients who presented with recurrent angioedema attacks, which was refractory to antihistamine therapy. Hence, they were treated with 300 mg omalizumab, every 4 weeks, for a period of 6 months. Both patients had shown a rapid response to the treatment and achieved complete resolution of symptoms without further AE attacks throughout the entire duration of the treatment period. After omalizumab's suspension, one patient remained symptom free for the following 6 months and the other patient had recurrence of symptoms after 2 months for which he was retreated with omalizumab and once again became symptom free. Although omalizumab seems to be effective as a prophylactic treatment for InH-AAE, the determining factors leading to the differences in time-to-relapse between patients after its suspension remain unclear. Further studies are needed in order to better determine the potential therapeutic application of omalizumab and its role in maintenance therapy.

References

Aug 26, 1978·British Medical Journal·R A Thompson, D D Felix-Davies
Jan 1, 1988·Acta Obstetricia Et Gynecologica Scandinavica·O M Håkansson
Jun 23, 1999·The American Journal of Medicine·M CicardiA Agostoni
Mar 22, 2005·Allergologia et immunopathologia·P GonzálezE Niveiro
Oct 13, 2007·The Journal of Allergy and Clinical Immunology·Mark F SandsStanley A Schwartz
Oct 4, 2011·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Sassan Ghazan-Shahi, Anne K Ellis
May 26, 2012·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·I Del CorsoP Migliorini
Mar 23, 2013·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·C SauleA Gompel
Apr 12, 2013·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Antonie von WebskyKristine Breuer
May 28, 2013·The American Journal of Emergency Medicine·Vincenzo MontinaroLoreto Gesualdo
Aug 31, 2013·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Tiffany Biason DyLarry Bernstein
Feb 26, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Alalia Berry, Rafael Firszt
Mar 29, 2014·Allergy·M CicardiUNKNOWN HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology)
May 9, 2014·Asia Pacific Allergy·Ayse Bilge Ozturk, Emek Kocaturk
Dec 3, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Mark C StahlJonathan A Bernstein
Mar 10, 2015·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Julián AzofraMarta Ferrer
Aug 11, 2015·Case Reports in Immunology·Amit FrenkelMoti Klein
Sep 6, 2015·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jodi ShrobaJay Portnoy
Apr 27, 2016·Clinical Reviews in Allergy & Immunology·Maddalena Alessandra WuMarco Cicardi
May 5, 2016·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Carmela GravanteGianni Marone
Jun 11, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·A M Giménez-ArnauM Maurer
Nov 9, 2016·Journal of Clinical Immunology·Charles FaisantLaurence Bouillet
Sep 2, 2017·Clinical and Translational Allergy·Martin Christian BucherUrs Christian Steiner

❮ Previous
Next ❯

Citations

Jan 19, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·V Zampeli, M Magerl
Jul 30, 2019·European Journal of Immunology·Lorenzo CosmiFrancesco Annunziato
Feb 20, 2020·Current Opinion in Allergy and Clinical Immunology·Camila Lopes Veronez, Anete Sevciovic Grumach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Julián AzofraMarta Ferrer
The Journal of Allergy and Clinical Immunology
Mark F SandsStanley A Schwartz
The American Journal of Medicine
Marco CicardiA Agostoni
Journal of Investigational Allergology & Clinical Immunology
C ColásT Caballero
© 2022 Meta ULC. All rights reserved